Evidence map›Paper›PMID 32743604›Full record

ArticlemedRxiv : the preprint server for health sciences2020

Clinical Impact, Costs, and Cost-Effectiveness of Expanded SARS-CoV-2 Testing in Massachusetts.

Anne M Neilan, Elena Losina, Audrey C Bangs, Clare Flanagan, Christopher Panella, G Ege Eskibozkurt, Amir Mohareb, Emily P Hyle, Justine A Scott, Milton C Weinstein and 7 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 26 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 3 countries.

Anne M NeilanDivision of General Academic Pediatrics, Department of Pediatrics, Massachusetts General Hospital, Boston, MA.
Elena LosinaHarvard Medical School, Boston, MA.
Audrey C BangsMedical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA.
Clare FlanaganMedical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA.
Christopher PanellaMedical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA.
G Ege EskibozkurtMedical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA.
Amir MoharebDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA.
Emily P HyleDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA.
Justine A ScottMedical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA.
Milton C WeinsteinDepartment of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Mark J SiednerDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA.
Krishna P ReddyMedical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA.
Guy HarlingAfrica Health Research Institute, KwaZulu-Natal, South Africa.
Kenneth A FreedbergDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA.
Fatma M SheblMedical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA.
Pooyan KazemianMedical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA.
Andrea L CiaranelloDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA.
Harvard University · USMassachusetts General Hospital · USBoston University · US

Funding

PROGRAM FOR AIDS CLINICAL RESEARCH TRAINING (PACRT)T32AI007433 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI MARK J SIEDNER · 1992 to 2026
$11.4M
Diagnosing and preventing HIV infection in adolescents and young adults in the US: clinical impact and cost-effectivenessK08HD094638 · NICHD · MASSACHUSETTS GENERAL HOSPITAL · PI NEILAN, ANNE · 2018 to 2023
$936k
NIAID NIH HHS T32 AI007433NICHD NIH HHS K08 HD094638Wellcome Trust
6 · The paper itself

Abstract

Background We projected the clinical and economic impact of alternative testing strategies on COVID-19 incidence and mortality in Massachusetts using a microsimulation model. Methods We compared five testing strategies: 1) PCR-severe-only: PCR testing only patients with severe/critical symptoms; 2) Self-screen: PCR-severe-only plus self-assessment of COVID-19-consistent symptoms with self-isolation if positive; 3) PCR-any-symptom: PCR for any COVID-19-consistent symptoms with self-isolation if positive; 4) PCR-all: PCR-any-symptom and one-time PCR for the entire population; and, 5) PCR-all-repeat: PCR-all with monthly re-testing. We examined effective reproduction numbers (R

Identifiers

PMID32743604
PMCPMC7386528
OpenAlexW3044702881

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.